Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• SHP2 inhibition is a promising cancer therapy, but resistance limits its effectiveness.
• Mechanisms of resistance to SHP2 inhibitors necessitate novel therapeutic strategies.
• Targeting NAMPT offers a potential approach to overcome SHP2 inhibitor resistance.

Purpose of the Study:

• To identify a dual inhibitor targeting both SHP2 and NAMPT.
• To evaluate the efficacy of a novel dual inhibitor in overcoming resistance to SHP2 inhibition.
• To assess the therapeutic potential of dual SHP2 and NAMPT inhibition in preclinical cancer models.

Main Methods:

• Development and characterization of compound A4 as a dual SHP2 and NAMPT inhibitor.
• Assessment of A4's efficacy in inhibiting proliferation in SHP099-insensitive cancer cell lines.
• Evaluation of A4's impact on PD-L1-mediated immunosuppression.
• Testing of A4's in vivo antitumor efficacy and immunomodulatory effects in mouse models.

Main Results:

• Compound A4 demonstrated potent dual inhibitory activity against SHP2 and NAMPT.
• A4 effectively inhibited proliferation in tumor cells resistant to SHP099.
• A4 reversed PD-L1-mediated immunosuppression and promoted antitumor immunity.
• Significant in vivo antitumor efficacy was observed in MDA-MB-231 and 4T1 mouse models.

Conclusions:

• A4 is a promising dual SHP2 and NAMPT inhibitor.
• Dual inhibition of SHP2 and NAMPT represents a novel strategy to overcome resistance to allosteric SHP2 inhibitors.
• A4 holds potential as a new therapeutic agent for cancer treatment.